Overview

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is an extension of a previous study (ALK9072-003EXT). The purpose of this study is to continue to evaluate the long-term safety and durability of effect of ALKS 9072 in subjects with stable schizophrenia, and to allow subjects who are doing well on ALKS 9072 to continue treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Alkermes, Inc.